In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.

Abstract

NXL104, a novel β-lactamase inhibitor, was tested at a constant concentration of 4 μg/ml in combination with ceftazidime (CAZ), with and without added metronidazole, against 396 β-lactamase-producing strains of anaerobic bacteria. MIC(50)/MIC(90) values for Bacteroides fragilis and the B. fragilis group were 8/16 and 64/>128 μg/ml, respectively. Although CAZ-NXL104 had limited activity against most anaerobic strains, in combination with metronidazole it shows potential for treating mixed infections involving resistant Enterobacteriaceae and anaerobes.

DOI: 10.1128/AAC.01682-10
02040201520162017
Citations per Year

Citation Velocity: 9

Averaging 9 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Citron2011InVA, title={In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.}, author={Diane M. Citron and Kerin L. Tyrrell and Vreni Merriam and Ellie J. C. Goldstein}, journal={Antimicrobial agents and chemotherapy}, year={2011}, volume={55 7}, pages={3616-20} }